Meeting
2020 ASCO Virtual Scientific Program
Impact of lymphopenia on survival for elderly patients with glioblastoma: A secondary analysis of the CCTG CE.6 (EORTC 26062-22061, TROG03.01) randomized clinical trial.
Authors
Andrew Jehyun Song
Sidney Kimmel Cancer Center, Philadelphia, PA
Andrew Jehyun Song , Keyue Ding , Normand Laperriere , James R. Perry , Warren P. Mason , Chad Winch , Christopher J. O'Callaghan , Johan Menten , Alba Ariela Brandes , Claire Phillips , Michael F. Fay , Ryo Nishikawa , David Osoba , Gregory Cairncross , Wilson Roa , Wolfgang Wick , Wenyin Shi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT00482677
Citation
J Clin Oncol 38: 2020 (suppl; abstr 2547)
DOI
10.1200/JCO.2020.38.15_suppl.2547
Abstract #
2547
Poster Bd #
38
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Stratified monotherapy approach according to MGMT methylation status in elderly patients with glioblastoma.
First Author: Mitsuaki Shirahata
Poster
2014 ASCO Annual Meeting
Survival and quality of life in the randomized, multicenter GLARIUS trial investigating bevacizumab/irinotecan versus standard temozolomide in newly diagnosed, MGMT-non-methylated glioblastoma patients.
First Author: Ulrich Herrlinger
Poster
2023 ASCO Annual Meeting
Short-length DNA fragments in plasma to predict clinical outcome in unresected glioblastoma patients.
First Author: Maxime Fontanilles
Poster
2022 ASCO Annual Meeting
Bortezomib sensitization of recurrent glioblastoma with unmethylated MGMT promoter to temozolomide, a phase II study (NCT03643549).
First Author: Dorota Goplen